TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02101905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib Ditosylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of tumor

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of tumor
Study: NCT02266160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream 5%
Description: the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: cetomacrogol cream (lotion cream)
Description: lotion cream that does not contain active drug. has no contraindications
Study: NCT02695381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac-lidocaine topical patch
Description: Once daily
Study: NCT03274622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact Parent Training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Impact
Study: NCT06177002

Intervention type: DIAGNOSTIC_TEST
Intervention: Collection of biological data
Description: Biological sample will be collected from the COVID19 patients and from healthy donors
Study: NCT02649595

Intervention type: OTHER
Group type: OTHER
Intervention: Red Cross Respite care
Description: See detailed description.
Study: NCT02244112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
Study: NCT02449252

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation involved-site radiotherapy (ISRT)
Description: six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Consolidation involved-field radiotherapy (IFRT)
Description: six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy\~30Gy in 12\~15 fractions of 2 Gy 5 days per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: patients in both arms will be given cyclophosphamide chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: patients in both arms will be given cyclophosphamide chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: patients in both arms will be given cyclophosphamide chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: patients in both arms will be given cyclophosphamide chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: patients in both arms will be given cyclophosphamide chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: patients in both arms will be given cyclophosphamide chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: patients in both arms will be given cyclophosphamide chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: patients in both arms will be given cyclophosphamide chemotherapy.
Study: NCT02695381

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT02550067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMPA
Description: Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
Study: NCT03375606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL730
Description: Solution for IV infusion
Study: NCT02550067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LNG
Description: Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copper IUD
Description: Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
Study: NCT02571816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2215
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2215
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2215
Description: oral
Study: NCT04689061

Intervention type: DEVICE
Intervention: Arthrex FastThread Interference Screw
Description: The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping. The Arthrex PEEK and Biocomposite FastThread Interference Screws have a tapered hexalobe design along the entire length of the screw to maximize transfer of torque and reduce screw stripping
Study: NCT03127358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AiCure
Description: Smartphone App

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AiCure with gamification
Description: Smartphone App with gaming.
Study: NCT01118377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was supplied as film-coated tablets.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
Study: NCT01091454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brostallicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT00575523

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
Study: NCT03375606

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution for IV infusion
Study: NCT00575523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
Study: NCT02502396

Intervention type: OTHER
Intervention: Retrospective Chart Review
Description: Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
Study: NCT03696771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NJH395
Description: Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
Study: NCT02126878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenalog
Study: NCT01984086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)
Description: Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)
Description: Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)
Description: Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)
Description: Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Diskus 200mcg Blister
Description: Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI 100mcg
Description: Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate UD-DPI Blister (selected from Part A)
Description: Formulation will be determined depending on the outcome of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)
Description: Formulation will be determined depending on the outcome of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Diskus 200mcg Blister without activated charcoal
Description: Formulation will be determined depending on the outcome of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol Diskus 200mcg Blister with activated charcoal
Description: Formulation will be determined depending on the outcome of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI 100mcg without activated charcoal
Description: Formulation will be determined depending on the outcome of Part A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI 100mcg with activated charcoal
Description: Formulation will be determined depending on the outcome of Part A.
Study: NCT01175317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid optimization
Description: Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.

Intervention type: OTHER
Group type: OTHER
Intervention: Regimen based on expertise anaesthesist
Description: Fluid regimen based on expertise anaesthesist
Study: NCT01711710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cohesive Gel Breast Implant
Description: Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction.
Study: NCT02220478

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Lateral Approach Total Hip Arthroplasty
Description: All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Lateral Approach Total Hip Arthroplasty
Description: All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
Study: NCT04738565

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Description: The mixture of Lactobacillus rhamnosus ŁOCK 0900, Lactobacillus rhamnosus ŁOCK 0908 and Lactobacillus casei ŁOCK 0919 administered once a day at a dose of one billion for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin comparable in color, texture and taste to the probiotic mixture administered once a day for 3 months.
Study: NCT04275193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zishenqing
Description: Zishenqing Granule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Granule manufactured to mimic Zishenqing(containing 10% composition)
Study: NCT03443037

Intervention type: DRUG
Intervention: amantadine sulphate
Study: NCT01305733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
Description: The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: saline
Study: NCT03118804

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Lung Tidal Distribution With EIT
Description: Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
Study: NCT05339763

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy
Description: exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chemoradiotherapy
Description: exposure of patients with rectal cancer to radiotherapy and assessment of their bowel function after surgery
Study: NCT02108106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: A range of doses of AG-348 will be tested based on assessment of safety and tolerability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00238212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03932188

Intervention type: BEHAVIORAL
Intervention: Mental Health Assessments and Computerized Cognitive Test
Description: Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.

Intervention type: BEHAVIORAL
Intervention: Mental Health Assessments and Computerized Cognitive Test
Description: Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.

Intervention type: DEVICE
Intervention: MRI scan
Description: Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.

Intervention type: DEVICE
Intervention: MRI scan
Description: Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
Study: NCT02496702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training on Interactive Modulare Tiles
Description: Training with the Interactive Modulare Tiles
Study: NCT01060137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl matrix
Description: Fentanyl transdermal patch 12 - 25mcg/hr
Study: NCT03458546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
Study: NCT00552097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe (plus simvastatin)
Description: oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (plus simvastatin)
Description: tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
Study: NCT02227771

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Study: NCT01314352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine Tablets, 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine Tablets, 5 mg
Study: NCT00184041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine
Description: Induction I/II, consolidation I/II/III/IV and Maintenance
Study: NCT04651881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: 1 Cap., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: 1 Tab., single oral administration under fed condition
Study: NCT04058054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraStat Gel
Description: Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biafine
Description: Administered 0.025 gm of Biafine per subject on day 1 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histamine
Description: Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline (0.9% NaCl)
Description: Administered 1 drop of saline per subject on day 1 of the study.
Study: NCT03996434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropin
Description: withholding gonadotropin administration for at least 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antagonist
Description: Cetrorelix acetate 0.25 mg
Study: NCT00325286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Plus Extended- Release Carbamazepine
Description: Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
Study: NCT04743700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Piezocisions with the help of piezotome , mesial and distal to a canine (in a vertical line) with the help of piezotome. These piezocisions will be performed on the buccal cortical bone only, 2-3mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle . The exact location of incision will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added and then 5mm incision is given in gingiva and overlying mucoperiosteum in a vertical line apically to expose the underlying bone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations
Description: Three MOPs mesial and three MOPs distal to canine(in a vertical line) with the help of minisrew implant driver (fig.2). These MOPs will be performed on the buccal cortical bone only, 2-3 mm below the alveolar crest level, 2mm deep into the bone under local anaesthesia (2% lidocaine with 1:100,000 epinephrine) and with standard asepsis, and no flap will be raised. The exact location of first MOP will be determined by transgingival probing mesial and distal to the canine to know the alveolar crest level and to this measurement 2-3 mm is added. The location of second MOP at 5mm apically in a vertical line and third MOP at 5 mm apically to second MOP